XXXXXX INFORMATION. The Company agrees that any information or advice rendered by Xxxxxx in connection with this engagement is for the confidential use of the Company only in their evaluation of the Placement and, except as otherwise required by law, the Company will not disclose or otherwise refer to the advice or information in any manner without Xxxxxx’x prior written consent.
XXXXXX INFORMATION. I will provide Lender with updated financial or credit information upon Lender’s reasonable request and notice. Subject to applicable law, Lender may obtain consumer reports from consumer reporting agencies as part of reviewing my Loan.
XXXXXX INFORMATION. The Company agrees that any information or advice rendered by Xxxxxx in connection with this engagement is for the confidential use of the Company only in their evaluation of the Placement and, except as otherwise required by law, the Company will not disclose or otherwise refer to the advice or information in any manner without Xxxxxx’x prior written consent. Notwithstanding the foregoing, the Company may file this Agreement and any Transaction Document with the Commission in any filing made by the Company pursuant to the Securities Act, the Exchange Act or the rules and regulations thereunder, and may refer to Xxxxxx’x engagement hereunder and the terms of this Agreement in any such filing (including any exhibit thereto).
XXXXXX INFORMATION. The information relating to Xxxxxx and its Subsidiaries that is provided by Xxxxxx or its representatives for inclusion in, or incorporation by reference into, the Joint Proxy Statement and Registration Statement, or in any application, notification or other document filed with any other Regulatory Agency or other Governmental Entity in connection with the transactions contemplated by this Agreement, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances in which they are made, not misleading. The portions of the Joint Proxy Statement relating to Xxxxxx and its Subsidiaries and other portions within the reasonable control of Xxxxxx and its Subsidiaries will comply in all material respects with the provisions of the Exchange Act and the rules and regulations thereunder.
XXXXXX INFORMATION. The parties hereto acknowledge and agree that, for all purposes of this Agreement, Xxxxx’x Information consists solely of the statements concerning Cowen contained in the sixth, seventh, eighth and ninth paragraphs under the heading “Underwriting” in the Prospectus.
XXXXXX INFORMATION. All information furnished below by the undersigned for use in the Registration Statement on Form S-3 is, and on the date such shares registered thereunder, will be true, correct, and complete in all material respects, and does not, and on the date on which the undersigned sells such shares, will not, contain any untrue statement of a material fact or omit to state any material fact necessary to make such information not misleading. By completing and returning this information statement, the undersigned hereby consents to the use of its, address, and share ownership information in the Form S-3 of SangStat Medical Corporation.
A. Date. Fill in Date: __________________________
B. Name. Print: Print and sign name or names ______________________________ exactly as name or names appear on share certificate. If certificate ______________________________ is held in more than one name, all must sign. Sign: ______________________________ ______________________________
XXXXXX INFORMATION. (If the Party completing this EDS is Vendor supplying a Good or Service to CHA)
1. Vendor’s name and title
2. Address
3. Brief background including but not limited to:
a. When was the business established?
b. Headquarters and/or primary office.
c. Years of experience in the area for which you are being awarded.
d. Current or experience and/or history with CHA SECTION II -- DISCLOSURE OF OWNERSHIP INTERESTS
A. NATURE OF DISCLOSING PARTY
1. Indicate the nature of the Disclosing Party: [ ] Individual [ ] Limited liability company* [ ] Publicly registered business corporation [ ] Limited liability partnership* [ ] Privately held business corporation [ ] Joint venture* [ ] Sole proprietorship [ ] Not-for-profit corporation [ ] General partnership* (Is the not-for-profit corporation also a 501(c)(3))? [ ] Yes [ ] No [ ] Limited partnership* [ ] Trust [ ] Other (please specify)
XXXXXX INFORMATION. The Company agrees that any information (including the name of any potential investor(s) procured by Xxxxxx) or advice rendered by Xxxxxx in connection with this engagement is for the confidential use of the Company only in their evaluation of the Placement and, except as otherwise required by law or the regulations of the NYSE Amex Equities Market, the Company will not disclose or otherwise refer to the advice or information in any manner without Xxxxxx’x prior written consent (unless such information or advice is otherwise in the public domain through no disclosure by the Company).
XXXXXX INFORMATION. Xxxxxx will identify knowledgeable and qualified professionals readily accessible who will provide information and respond to queries, as follows:
(a) Notify BioTE in writing of any regulatory agency communications or contacts related to the Products and provide a copy of documents requested and left by the authorities within one (1) business day.
(b) Notify BioTE in writing of stability trends or non-conformance to specification within three (3) business days.
(c) Provide an investigation report for adverse events within 30 business days of Xxxxxx’x receipt of such complaints, or immediately upon completion of the investigation report, whichever is sooner.
(d) Meet with BioTE, as necessary, to discuss technical matters relating to the manufacture of Products.
(e) Advise BioTE in writing of major unplanned process deviations or confirmed out-of-specification results within one (1) business day of Xxxxxx’x knowledge of the same.
(f) Provide a COA (via electronic mail to BioTE’s QA department) for each finished batch shipment of Product.
XXXXXX INFORMATION. In connection with this Agreement and the transactions contemplated hereby, such Shareholder is relying solely on the information relating to Xxxxxx’x business, finances and operations contained in filings by Xxxxxx with the Securities and Exchange Commission and further acknowledges that neither Ventures nor Xxxxxx makes any representation or warranty with respect to any matters relating to Xxxxxx, its business, financial condition, results of operations, prospects or otherwise, except to the extent expressly provided in Article III hereof.
